Current therapies for hepatorenal syndrome

被引：0
作者：
Bonder A. [1 ]
Botero M.L. [2 ]
Cardenas A. [3 ,4 ]
机构：
[1] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
[2] SolutioPath- Integrated Pathology Services, Barcelona
[3] GI Unit-Institut de Malalties Digestives I Metaboliques, University of Barcelona, Hospital Clinic, Barcelona
[4] Institute of Digestive Diseases and Metabolism, University of Barcelona, Hospital Clinic, 08036 Barcelona, Villarroel 170
来源：
Current Hepatology Reports | 2014年 / 13卷 / 1期
关键词：
Acute kidney injury; Albumin; Ascites; Cirrhosis; Hepatorenal syndrome; Midodrine; Noradrenaline; Ocreotide; Portal hypertension; Terlipressin;
D O I：
10.1007/s11901-014-0217-7
中图分类号：
学科分类号：
摘要：
Hepatorenal syndrome (HRS) is a feared common complication of patients with cirrhosis. This syndrome is mainly characterized by functional renal failure due to renal vasoconstriction in the absence of underlying kidney pathology. The pathogenesis of HRS is complex and a final result of an extreme underfilling of the arterial circulation secondary to an arterial vasodilation located in the splanchnic circulation. This phenomenon leads to a compensatory response with activation of vasoconstrictors that cause intense renal vasoconstriction and kidney failure. The diagnosis of HRS is based on established diagnostic criteria aimed at excluding nonfunctional causes of renal failure. However in recent years the diagnosis of renal failure in patients with cirrhosis has also been adapted to include the acute kidney injury criteria proposed by the acute kidney injury network. The prognosis of patients with HRS is poor, especially in those who have a rapidly progressive course. Liver transplantation is the best option in suitable candidates, but difficult to implement in all patients due to the poor prognosis of many patients. Pharmacological therapies based on the use of vasoconstrictor drugs plus intravenous albumins are the standard first line of therapy. Other treatments such as transjugular intrahepatic portosystemic shunts and renal replacement may be effective but experience is limited. HRS prophylaxisis recommended in patients with spontaneous bacterial peritonitis, advanced cirrhosis and those with severe acute alcoholic hepatitis. © 2014 Springer Science+Business Media.
引用
收藏
页码：74 / 80
页数：6
相关论文
共 52 条
  • [1] Cardenas A., Gines P., Therapy insight: Management of hepatorenal syndrome, Nature Clinical Practice Gastroenterology and Hepatology, 3, 6, pp. 338-348, (2006)
  • [2] Gines P., Schrier R.W., Renal failure in cirrhosis, N Engl J Med, 361, pp. 1279-1290, (2009)
  • [3] Salerno F., Gerbes A., Gines P., Wong F., Arroyo V., Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 9, pp. 1310-1318, (2007)
  • [4] EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, J Hepatol, 53, 3, pp. 397-417, (2010)
  • [5] Arroyo V., Fernandez J., Management of hepatorenal syndrome in patients with cirrhosis, Nat Rev Nephrol, 7, pp. 517-526, (2011)
  • [6] Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., Rodes J., Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis, Hepatology, 8, pp. 1151-1157, (1988)
  • [7] Ruiz-del-Arbol L., Urman J., Fernandez J., Gonzalez M., Navasa M., Monescillo A., Albillos A., Jimenez W., Arroyo V., Systemic, Renal, and Hepatic Hemodynamic Derangement in Cirrhotic Patients with Spontaneous Bacterial Peritonitis, Hepatology, 38, 5, pp. 1210-1218, (2003)
  • [8] Krag A., Bendtsen F., Henriksen J.H., Moller S., Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites, Gut, 59, pp. 105-110, (2010)
  • [9] Fede G., D'Amico G., Arvaniti V., Et al., Renal failure and cirrhosis: A systematic review of mortality and prognosis, J Hepatol, 56, pp. 810-818, (2012)
  • [10] Tsai M.H., Peng Y.S., Chen Y.C., Et al., Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock, Hepatology, 43, pp. 673-681, (2006)
123456